527 related articles for article (PubMed ID: 14565644)
1. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia.
Linn YC; Hui KM
Leuk Lymphoma; 2003 Sep; 44(9):1457-62. PubMed ID: 14565644
[TBL] [Abstract][Full Text] [Related]
2. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
[TBL] [Abstract][Full Text] [Related]
3. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation.
Alvarnas JC; Linn YC; Hope EG; Negrin RS
Biol Blood Marrow Transplant; 2001; 7(4):216-22. PubMed ID: 11349808
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell.
Linn YC; Lau SK; Liu BH; Ng LH; Yong HX; Hui KM
Immunology; 2009 Mar; 126(3):423-35. PubMed ID: 18778291
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
6. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.
Pievani A; Borleri G; Pende D; Moretta L; Rambaldi A; Golay J; Introna M
Blood; 2011 Sep; 118(12):3301-10. PubMed ID: 21821703
[TBL] [Abstract][Full Text] [Related]
7. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
[TBL] [Abstract][Full Text] [Related]
8. The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells.
Rettinger E; Kuçi S; Naumann I; Becker P; Kreyenberg H; Anzaghe M; Willasch A; Koehl U; Bug G; Ruthardt M; Klingebiel T; Fulda S; Bader P
Cytotherapy; 2012 Jan; 14(1):91-103. PubMed ID: 21973023
[TBL] [Abstract][Full Text] [Related]
9. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.
Lu PH; Negrin RS
J Immunol; 1994 Aug; 153(4):1687-96. PubMed ID: 7519209
[TBL] [Abstract][Full Text] [Related]
10. Can the dual-functional capability of CIK cells be used to improve antitumor effects?
Wang X; Yu W; Li H; Yu J; Zhang X; Ren X; Cao S
Cell Immunol; 2014 Jan; 287(1):18-22. PubMed ID: 24355711
[TBL] [Abstract][Full Text] [Related]
11. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts.
Linn YC; Lau LC; Hui KM
Br J Haematol; 2002 Jan; 116(1):78-86. PubMed ID: 11841399
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission.
Linn YC; Yong HX; Niam M; Lim TJ; Chu S; Choong A; Chuah C; Goh YT; Hwang W; Loh Y; Ng HJ; Suck G; Chan M; Koh M
Cytotherapy; 2012 Aug; 14(7):851-9. PubMed ID: 22799277
[TBL] [Abstract][Full Text] [Related]
13. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL.
Boeck CL; Amberger DC; Doraneh-Gard F; Sutanto W; Guenther T; Schmohl J; Schuster F; Salih H; Babor F; Borkhardt A; Schmetzer H
J Immunother; 2017; 40(6):224-248. PubMed ID: 28557814
[TBL] [Abstract][Full Text] [Related]
14. Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells.
Hongeng S; Petvises S; Worapongpaiboon S; Rerkamnuaychoke B; Pakakasama S; Jootar S
Int J Hematol; 2003 Feb; 77(2):175-9. PubMed ID: 12627854
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow mesenchymal stem cells reduce the antitumor activity of cytokine-induced killer/natural killer cells in K562 NOD/SCID mice.
Li Y; Qu YH; Wu YF; Wang XP; Wei J; Huang WG; Zhou DH; Fang J; Huang K; Huang SL
Ann Hematol; 2011 Aug; 90(8):873-85. PubMed ID: 21234566
[TBL] [Abstract][Full Text] [Related]
16. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A
Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486
[TBL] [Abstract][Full Text] [Related]
17. Human interferon-alpha increases the cytotoxic effect of CD56(+) cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell lines.
Durrieu L; Gregoire-Gauthier J; Dieng MM; Fontaine F; le Deist F; Haddad E
Cytotherapy; 2012 Nov; 14(10):1245-57. PubMed ID: 22974386
[TBL] [Abstract][Full Text] [Related]
18. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells.
Carlens S; Gilljam M; Chambers BJ; Aschan J; Guven H; Ljunggren HG; Christensson B; Dilber MS
Hum Immunol; 2001 Oct; 62(10):1092-8. PubMed ID: 11600215
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity of cytokine-induced killer cells coated with bispecific antibody against acute myeloid leukemia cells.
Kaneko T; Fusauch Y; Kakui Y; Okumura K; Mizoguchi H; Oshimi K
Leuk Lymphoma; 1994 Jul; 14(3-4):219-29. PubMed ID: 7950910
[TBL] [Abstract][Full Text] [Related]
20. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma.
Shi M; Zhang B; Tang ZR; Lei ZY; Wang HF; Feng YY; Fan ZP; Xu DP; Wang FS
World J Gastroenterol; 2004 Apr; 10(8):1146-51. PubMed ID: 15069715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]